F. Asuncion

发表

Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats

P. Kostenuik, M. Stolina, H. Ke, 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Skeletal deterioration induced by RANKL infusion: a model for high-turnover bone disease

P. Kostenuik, T. Bateman, S. Morony, 2008, Osteoporosis International.

Soluble RANKL Induces High Bone Turnover and Decreases Bone Volume, Density, and Strength in Mice

P. Kostenuik, T. Bateman, S. Morony, 2008, Calcified Tissue International.

Denosumab, a Fully Human Monoclonal Antibody to RANKL, Inhibits Bone Resorption and Increases BMD in Knock‐In Mice That Express Chimeric (Murine/Human) RANKL

P. Kostenuik, S. Morony, W. Dougall, 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin.

P. Kostenuik, M. Stolina, H. Ke, 2009, Bone.

Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones

D. Lacey, Susan Y. Smith, M. Stolina, 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Progressive increases in bone mass and bone strength in an ovariectomized rat model of osteoporosis after 26 weeks of treatment with a sclerostin antibody.

P. Kostenuik, M. Stolina, H. Ke, 2014, Endocrinology.

Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus

L. Hofbauer, M. Stolina, C. Hamann, 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats.

P. Kostenuik, M. Stolina, H. Ke, 2011, Endocrinology.

Sclerostin Antibody Treatment Improves the Bone Phenotype of Crtap–/– Mice, a Model of Recessive Osteogenesis Imperfecta

B. Dawson, Brendan H. Lee, Yuqing Chen, 2016, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

RANKL Inhibition with Osteoprotegerin Increases Bone Strength by Improving Cortical and Trabecular bone Architecture in Ovariectomized Rats

P. Kostenuik, M. Stolina, H. Ke, 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

FGF21 Is Not a Major Mediator for Bone Homeostasis or Metabolic Actions of PPARα and PPARγ Agonists

M. Stolina, N. Chinookoswong, M. Véniant, 2017, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

FGF 21 is not a major mediator for bone homeostasis or metabolic actions of PPAR and PPAR agonists † Running Title : FGF 21 on bone and actions of PPAR PPAR

M. Stolina, N. Chinookoswong, M. Véniant, 2016 .

RANKL is a Marker and Mediator of Local and Systemic Bone Loss in Two Rat Models of Inflammatory Arthritis

P. Kostenuik, M. Stolina, G. Schett, 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy.

P. Kostenuik, S. Morony, C. Capparelli, 2005, Endocrinology.

The RANKL Inhibitor Osteoprotegerin (OPG) Causes Greater Suppression of Bone Resorption and Hypercalcemia Compared to Bisphosphonates in Two Models of Humoral Hypercalcemia of Malignancy

P. Kostenuik, S. Morony, C. Capparelli, 2005 .

One Year of Transgenic Overexpression of Osteoprotegerin in Rats Suppressed Bone Resorption and Increased Vertebral Bone Volume, Density, and Strength

P. Kostenuik, M. Stolina, H. Ke, 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Increased callus mass and enhanced strength during fracture healing in mice lacking the sclerostin gene.

H. Ke, H. Tan, W. S. Simonet, 2011, Bone.

Targeted Deletion of the Sclerostin Gene in Mice Results in Increased Bone Formation and Bone Strength

P. Kostenuik, S. Morony, D. Lacey, 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression

J. Zwerina, G. Schett, J. Distler, 2010, Annals of the rheumatic diseases.

Bone turnover markers in peripheral blood and marrow plasma reflect trabecular bone loss but not endocortical expansion in aging mice.

P. Kostenuik, M. Stolina, M. Ominsky, 2012, Bone.

Sclerostin Antibody Reverses Bone Loss by Increasing Bone Formation and Decreasing Bone Resorption in a Rat Model of Male Osteoporosis

H. Ke, W. S. Simonet, T. Wronski, 2018, Endocrinology.

The Candidate Neuroprotective Agent Artemin Induces Autonomic Neural Dysplasia without Preventing Peripheral Nerve Dysfunction

T. Juan, B. Bolon, J. Tarpley, 2004, Toxicologic pathology.

A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair

W. Richards, K. Gunasekaran, M. Stolina, 2016, Nature Communications.

Etelcalcetide (AMG 416), a peptide agonist of the calcium-sensing receptor, preserved cortical bone structure and bone strength in subtotal nephrectomized rats with established secondary hyperparathyroidism.

W. Richards, M. Stolina, J. Tomlinson, 2017, Bone.

Osteoprotegerin abrogated cortical porosity and bone marrow fibrosis in a mouse model of constitutive activation of the PTH/PTHrP receptor.

P. Kostenuik, R. Chiusaroli, E. Schipani, 2009, The American journal of pathology.

Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia.

P. Kostenuik, S. Morony, D. Lacey, 2006, Bone.

Dickkopf‐1 regulates bone formation in young growing rodents and upon traumatic injury

P. Kostenuik, D. Lacey, T. Horan, 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Dual Inhibition of the Wnt Inhibitors DKK1 and Sclerostin Promotes Fracture Healing and Increases the Density and Strength of Uninjured Bone

P. Kostenuik, M. Stolina, H. Ke, 2023, The Journal of bone and joint surgery. American volume.

Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats.

P. Kostenuik, M. Stolina, H. Ke, 2011, Endocrinology.